143 related articles for article (PubMed ID: 33887302)
21. Targeting gene expression of the mouse uroplakin II promoter to human bladder cells.
Zhu H; Zhang ZA; Xu C; Huang G; Zeng X; Wei S; Zhang Z; Guo Y
Urol Res; 2003 Mar; 31(1):17-21. PubMed ID: 12624658
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Katoh R; Kondo T
Anticancer Res; 2018 Aug; 38(8):4759-4766. PubMed ID: 30061246
[TBL] [Abstract][Full Text] [Related]
23. Altered expression of UPIa, UPIb, UPII, and UPIIIa during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats.
Zupančič D; Ovčak Z; Vidmar G; Romih R
Virchows Arch; 2011 May; 458(5):603-13. PubMed ID: 21301865
[TBL] [Abstract][Full Text] [Related]
24. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder?
Riedel I; Liang FX; Deng FM; Tu L; Kreibich G; Wu XR; Sun TT; Hergt M; Moll R
Eur J Cell Biol; 2005 Mar; 84(2-3):393-405. PubMed ID: 15819416
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
26. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Oliva E; Amin MB; Jimenez R; Young RH
Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
[TBL] [Abstract][Full Text] [Related]
27. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder.
Ellis CL; Chang AG; Cimino-Mathews A; Argani P; Youssef RF; Kapur P; Montgomery EA; Epstein JI
Am J Surg Pathol; 2013 Nov; 37(11):1756-60. PubMed ID: 24061521
[TBL] [Abstract][Full Text] [Related]
28. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
29. Selective immunohistochemical markers to distinguish between metastatic high-grade urothelial carcinoma and primary poorly differentiated invasive squamous cell carcinoma of the lung.
Gruver AM; Amin MB; Luthringer DJ; Westfall D; Arora K; Farver CF; Osunkoya AO; McKenney JK; Hansel DE
Arch Pathol Lab Med; 2012 Nov; 136(11):1339-46. PubMed ID: 23106579
[TBL] [Abstract][Full Text] [Related]
30. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.
Wang G; Xiao L; Zhang M; Kamat AM; Siefker-Radtke A; Dinney CP; Czerniak B; Guo CC
Hum Pathol; 2018 Sep; 79():57-65. PubMed ID: 29763719
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical Expression of Cyclin D1, Cytokeratin 20, and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by o-Nitroanisole in Fischer 344/N Rats.
Willson CJ; Flake GP; Sills RC; Kissling GE; Cesta MF
Vet Pathol; 2016 May; 53(3):682-90. PubMed ID: 26319780
[TBL] [Abstract][Full Text] [Related]
32. A MAPP Network study: overexpression of tumor necrosis factor-α in mouse urothelium mimics interstitial cystitis.
Yang W; Searl TJ; Yaggie R; Schaeffer AJ; Klumpp DJ
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F36-F44. PubMed ID: 29465304
[TBL] [Abstract][Full Text] [Related]
33. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall.
Wobker SE; Khararjian A; Epstein JI
Am J Surg Pathol; 2017 Apr; 41(4):557-563. PubMed ID: 28291125
[TBL] [Abstract][Full Text] [Related]
34. Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.
He XD; Wang ZP; Wei HY; Zhou Q; Wang DG; Tian JQ; Fu SJ; Rodriguez R
Urol Int; 2009; 82(2):209-13. PubMed ID: 19322012
[TBL] [Abstract][Full Text] [Related]
35. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer.
Olsburgh J; Harnden P; Weeks R; Smith B; Joyce A; Hall G; Poulsom R; Selby P; Southgate J
J Pathol; 2003 Jan; 199(1):41-9. PubMed ID: 12474225
[TBL] [Abstract][Full Text] [Related]
36. Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice.
Aboushwareb T; Zhou G; Deng FM; Turner C; Andersson KE; Tar M; Zhao W; Melman A; D'Agostino R; Sun TT; Christ GJ
Neurourol Urodyn; 2009; 28(8):1028-33. PubMed ID: 19267388
[TBL] [Abstract][Full Text] [Related]
37. Napsin A is a highly sensitive marker for nephrogenic adenoma: an immunohistochemical study with a specificity test in genitourinary tumors.
Sharifai N; Abro B; Chen JF; Zhao M; He H; Cao D
Hum Pathol; 2020 Aug; 102():23-32. PubMed ID: 32561332
[TBL] [Abstract][Full Text] [Related]
38. Uroplakin II outperforms uroplakin III in diagnostically challenging settings.
Smith SC; Mohanty SK; Kunju LP; Chang E; Chung F; Carvalho JC; Paner GP; Hansel DE; Luthringer DJ; de Peralta-Ventrurina MN; Amin MB
Histopathology; 2014 Jul; 65(1):132-8. PubMed ID: 24382161
[TBL] [Abstract][Full Text] [Related]
39. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract][Full Text] [Related]
40. Urothelial Differences in the Exstrophy-Epispadias Complex: Potential Implications for Management.
Kasprenski M; Michaud J; Yang Z; Maruf M; Benz K; Jayman J; Epstein J; Di Carlo H; Gearhart JP
J Urol; 2021 May; 205(5):1460-1465. PubMed ID: 33347773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
